{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:17:42Z","timestamp":1787019462326,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":1348,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["academicpathologyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Academic Pathology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1177\/2374289518811797","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T05:38:35Z","timestamp":1542778715000},"page":"2374289518811797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing"],"prefix":"10.1016","volume":"5","author":[{"given":"Justine M.","family":"Reschly-Krasowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0856-8402","authenticated-orcid":false,"given":"Matthew D.","family":"Krasowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1177\/2374289518811797_bib1","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.psc.2017.05.006","article-title":"Drugs of abuse","volume":"40","author":"Akerele","year":"2017","journal-title":"Psychiatr Clin North Am"},{"key":"10.1177\/2374289518811797_bib2","series-title":"Trends in Substance Use Disorders Among Adults Aged 18 or Older. CBHSQ Report","first-page":"1","author":"Lipari","year":"2013"},{"key":"10.1177\/2374289518811797_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00325481.2018.1407618","article-title":"Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin","volume":"130","author":"Pergolizzi","year":"2018","journal-title":"Postgrad Med"},{"key":"10.1177\/2374289518811797_bib4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/appi.ajp.2015.15020262","article-title":"Prescription opioid misuse, abuse, and treatment in the United States: an update","volume":"173","author":"Brady","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1177\/2374289518811797_bib5","first-page":"247","article-title":"Prescription sedative misuse and abuse","volume":"88","author":"Weaver","year":"2015","journal-title":"Yale J Biol Med"},{"key":"10.1177\/2374289518811797_bib6","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu Rev Public Health"},{"key":"10.1177\/2374289518811797_bib7","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1213\/ANE.0000000000002565","article-title":"Role of urine drug testing in the current opioid epidemic","volume":"125","author":"Mahajan","year":"2017","journal-title":"Anesth Analg"},{"key":"10.1177\/2374289518811797_bib8","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s13181-012-0274-7","article-title":"Laboratory testing for prescription opioids","volume":"8","author":"Milone","year":"2012","journal-title":"J Med Toxicol"},{"key":"10.1177\/2374289518811797_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cll.2012.06.004","article-title":"The utility of immunoassays for urine drug testing","volume":"32","author":"Melanson","year":"2012","journal-title":"Clin Lab Med"},{"key":"10.1177\/2374289518811797_bib10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.cll.2012.07.001","article-title":"Urine drug testing for pain management","volume":"32","author":"Magnani","year":"2012","journal-title":"Clin Lab Med"},{"key":"10.1177\/2374289518811797_bib11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/10550887.2010.509277","article-title":"Advanced urine toxicology testing","volume":"29","author":"Tenore","year":"2010","journal-title":"J Addict Dis"},{"key":"10.1177\/2374289518811797_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4065\/83.1.66","article-title":"Urine drug screening: practical guide for clinicians","volume":"83","author":"Moeller","year":"2008","journal-title":"Mayo Clinic Proc"},{"key":"10.1177\/2374289518811797_bib13","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jat\/32.8.530","article-title":"Urine drug testing of chronic pain patients: licit and illicit drug patterns","volume":"32","author":"Cone","year":"2008","journal-title":"J Anal Toxicol"},{"key":"10.1177\/2374289518811797_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1373\/clinchem.2008.118638","article-title":"Chemoinformatic methods for predicting interference in drug of abuse\/toxicology immunoassays","volume":"55","author":"Krasowski","year":"2009","journal-title":"Clin Chem"},{"key":"10.1177\/2374289518811797_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jat\/bku075","article-title":"False-positive interferences of common urine drug screen immunoassays: a review","volume":"38","author":"Saitman","year":"2014","journal-title":"J Anal Toxicol"},{"key":"10.1177\/2374289518811797_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-227X-9-5","article-title":"Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse\/toxicology screening in emergency medicine","volume":"9","author":"Krasowski","year":"2009","journal-title":"BMC Emerg Med"},{"key":"10.1177\/2374289518811797_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/AOG.0b013e318206c07c","article-title":"False-positive amphetamine toxicology screen results in three pregnant women using labetalol","volume":"117","author":"Yee","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1177\/2374289518811797_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/AOG.0b013e3182263f1b","article-title":"False-positive amphetamine toxicology screen results in three pregnant women using labetalol","volume":"118","author":"Duenas-Garcia","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1177\/2374289518811797_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/jat\/19.2.84","article-title":"A labetalol metabolite with analytical characteristics resembling amphetamines","volume":"19","author":"Gilbert","year":"1995","journal-title":"J Anal Toxicol"},{"key":"10.1177\/2374289518811797_bib20","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1001\/jama.286.24.3115","article-title":"Quinolones and false-positive urine screening for opiates by immunoassay technology","volume":"286","author":"Baden","year":"2001","journal-title":"JAMA"},{"key":"10.1177\/2374289518811797_bib21","doi-asserted-by":"crossref","first-page":"735","DOI":"10.5858\/134.5.735","article-title":"Interpretation and utility of drug of abuse immunoassays: lessons from laboratory drug testing surveys","volume":"134","author":"Melanson","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1177\/2374289518811797_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1309\/AJCPZ0DS4QLYNCQG","article-title":"Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology consultation on urine compliance testing and drug abuse screening","volume":"142","author":"Ward","year":"2014","journal-title":"Am J Clin Pathol"},{"key":"10.1177\/2374289518811797_bib23","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.2174\/13816128113199990622","article-title":"New designer drugs (synthetic cannabinoids and synthetic cathinones): review of literature","volume":"20","author":"Cottencin","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1177\/2374289518811797_bib24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.lfs.2013.07.023","article-title":"Bath salts and synthetic cathinones: an emerging designer drug phenomenon","volume":"97","author":"German","year":"2013","journal-title":"Life Sci"},{"key":"10.1177\/2374289518811797_bib25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/phar.1424","article-title":"\u201cNot for human consumption\u201d: a review of emerging designer drugs","volume":"34","author":"Musselman","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1177\/2374289518811797_bib26","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jat\/bkt031","article-title":"Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration","volume":"37","author":"Cone","year":"2013","journal-title":"J Anal Toxicol"},{"key":"10.1177\/2374289518811797_bib27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jat\/34.2.78","article-title":"Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine","volume":"34","author":"Gingras","year":"2010","journal-title":"J Anal Toxicol"},{"key":"10.1177\/2374289518811797_bib28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/ADM.0b013e31829084b7","article-title":"Substituted cathinone products: a new trend in \u201cbath salts\u201d and other designer stimulant drug use","volume":"7","author":"Gunderson","year":"2013","journal-title":"J Addict Med"},{"key":"10.1177\/2374289518811797_bib29","first-page":"1","article-title":"\u201cBath salts\u201d intoxication: a new recreational drug that presents with a familiar toxidrome","volume":"15","author":"Hall","year":"2013","journal-title":"CJEM"},{"key":"10.1177\/2374289518811797_bib30","first-page":"1","article-title":"Designer benzodiazepines: new drugs challenge laboratories","volume":"2018","author":"Marin","year":"2018","journal-title":"Clin Foren Toxicol News"},{"key":"10.1177\/2374289518811797_bib31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mcna.2018.02.010","article-title":"New and emerging illicit psychoactive substances","volume":"102","author":"Graddy","year":"2018","journal-title":"Med Clin North Am"},{"key":"10.1177\/2374289518811797_bib32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/wps.20236","article-title":"Designer benzodiazepines: a new challenge","volume":"14","author":"Moosmann","year":"2015","journal-title":"World Psychiatry"},{"key":"10.1177\/2374289518811797_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ajcp\/aqx138","article-title":"Newly emerging drugs of abuse and their detection methods: an ACLPS critical review","volume":"149","author":"Liu","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"10.1177\/2374289518811797_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.emc.2013.09.001","article-title":"Emerging drugs of abuse","volume":"32","author":"Nelson","year":"2014","journal-title":"Emerg Med Clin North Am"},{"key":"10.1177\/2374289518811797_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/dta.2003","article-title":"Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays","volume":"9","author":"Pettersson Bergstrand","year":"2017","journal-title":"Drug Test Anal"},{"key":"10.1177\/2374289518811797_bib36","doi-asserted-by":"crossref","first-page":"322","DOI":"10.3109\/15360288.2013.847889","article-title":"Demystifying analytical approaches for urine drug testing to evaluate medication adherence in chronic pain management","volume":"27","author":"McMillin","year":"2013","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1177\/2374289518811797_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1309\/AJCPMJKBC6VJA1SP","article-title":"A hybrid approach to urine drug testing using high-resolution mass spectrometry and select immunoassays","volume":"143","author":"McMillin","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"10.1177\/2374289518811797_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-3252-8_1","article-title":"Mass spectrometry in clinical laboratory: applications in therapeutic drug monitoring and toxicology","volume":"1383","author":"Garg","year":"2016","journal-title":"Methods Mol Biol"},{"key":"10.1177\/2374289518811797_bib39","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.cca.2012.10.026","article-title":"Implementation of liquid chromatography\/mass spectrometry into the clinical laboratory","volume":"420","author":"Wu","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1177\/2374289518811797_bib40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cll.2016.07.001","article-title":"Liquid chromatography-tandem mass spectrometry: an emerging technology in the toxicology laboratory","volume":"36","author":"Zhang","year":"2016","journal-title":"Clin Lab Med"},{"key":"10.1177\/2374289518811797_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1309\/AJCP6OAULC3CMFEJ","article-title":"The long and winding regulatory road for laboratory-developed tests","volume":"138","author":"Weiss","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1177\/2374289518811797_bib42","author":"Kane"},{"key":"10.1177\/2374289518811797_bib43","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1758-2946-6-22","article-title":"Using cheminformatics to predict cross reactivity of \u201cdesigner drugs\u201d to their currently available immunoassays","volume":"6","author":"Krasowski","year":"2014","journal-title":"J Cheminform"},{"key":"10.1177\/2374289518811797_bib44","series-title":"Toxicology and Drug Testing in the Medical Laboratory. CLSI Guideline C52","author":"Clinical and Laboratory Standards Institute","year":"2017"},{"key":"10.1177\/2374289518811797_bib45","author":"Lias"},{"key":"10.1177\/2374289518811797_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/15563650.2013.768344","article-title":"Cross-reactivity studies and predictive modeling of \u201cBath Salts\u201d and other amphetamine-type stimulants with amphetamine screening immunoassays","volume":"51","author":"Petrie","year":"2013","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1177\/2374289518811797_bib47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/FTD.0b013e31819c1b83","article-title":"Molecular similarity methods for predicting cross-reactivity with therapeutic drug monitoring immunoassays","volume":"31","author":"Krasowski","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1177\/2374289518811797_bib48","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1472-6890-14-33","article-title":"Cross-reactivity of steroid hormone immunoassays: clinical significance and two-dimensional molecular similarity prediction","volume":"14","author":"Krasowski","year":"2014","journal-title":"BMC Clin Pathol"}],"container-title":["Academic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2374289518811797","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2374289518811797","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2374289521003274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2374289521003274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2374289518811797","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:28:17Z","timestamp":1762496897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2374289521003274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":48,"alternative-id":["S2374289521003274"],"URL":"https:\/\/doi.org\/10.1177\/2374289518811797","relation":{},"ISSN":["2374-2895"],"issn-type":[{"value":"2374-2895","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Difficult Challenge for the Clinical Laboratory: Accessing and Interpreting Manufacturer Cross-Reactivity Data for Immunoassays Used in Urine Drug Testing","name":"articletitle","label":"Article Title"},{"value":"Academic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1177\/2374289518811797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 The Authors 2018","name":"copyright","label":"Copyright"}],"article-number":"2374289518811797"}}